drugset / Trial / NCT05673538
TT-00973-MS Tablets in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, open-label, phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TT-00973-MS tablets in patients with solid tumors.
Timeline
- Start
- 2023-01
- Primary completion
- 2024-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TT-00973-MS | Unknown | 2 mg | — |
| Subject | TT-00973-MS | Unknown | 5 mg | — |
| Subject | TT-00973-MS | Unknown | 10 mg | — |
| Subject | TT-00973-MS | Unknown | 17 mg | — |
| Subject | TT-00973-MS | Unknown | 25 mg | — |
| Subject | TT-00973-MS | Unknown | 32 mg | — |
| Subject | TT-00973-MS | Unknown | 40 mg | — |
| Subject | TT-00973-MS | Unknown | 50 mg | — |